Simó M, Porta O, Pubill J, Castillo M T, Mora I, Huguet E, Ortega J A, Martínez E
Departamento de Obstetricia y Ginecología, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España.
Departamento de Obstetricia y Ginecología, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España.
Actas Urol Esp. 2015 May;39(4):222-8. doi: 10.1016/j.acuro.2014.05.013. Epub 2014 Oct 25.
To assess the short-term compliance with fesoterodine treatment and to identify the reasons for lack of adherence and discontinuation in routine clinical practice. The secondary aim was to estimate the patient-reported outcomes.
This was an observational retrospective, multicenter study conducted in a sample of women with overactive bladder on fesoterodine treatment for at least three months. Adherence to medication was assessed using the Morisky-Green test. Patient-reported outcomes were assessed using the Incontinence Questionnaire Short Form (ICIQ-SF), Overactive Bladder Questionnaire Short Form (OAB-qSF), and Treatment Benefit Scale (TBS).
One hundred and twenty women with a mean age [standard deviation (SD)] of 62.2 (12.0) years with severe OAB [mean (SD) ICIQ-SF score 13.2 (4.0)] were included. 42.1% of the patients were considered compliant with fesoterodine treatment. The main causes for non-compliance/discontinuation stated by the remaining 57.9% of the patients were adverse events (62.2%) and lack of clinical benefits (20.0%). The illness status as well as the patient-perceived bother occasioned by the OAB symptoms and their impact on the quality of life improved significantly after three months on fesoterodine treatment (p<0.0001). Most of the patients stated that the current state of their urinary problems had greatly improved/ improved.
In routine clinical practice, a high percentage of patients were adherent to fesoterodine and perceived the benefit that the treatment provided them three months after starting treatment. However, more than half of the study population failed to comply or discontinued the treatment mainly due to intolerance or lack of efficacy.
评估非索罗定治疗的短期依从性，并确定在常规临床实践中不依从和停药的原因。次要目的是评估患者报告的结局。
这是一项观察性回顾性多中心研究，样本为接受非索罗定治疗至少三个月的膀胱过度活动症女性患者。使用Morisky-Green测试评估药物依从性。使用尿失禁问卷简表（ICIQ-SF）、膀胱过度活动症问卷简表（OAB-qSF）和治疗益处量表（TBS）评估患者报告的结局。
纳入了120名平均年龄[标准差（SD）]为62.2（12.0）岁、患有严重膀胱过度活动症[平均（SD）ICIQ-SF评分为13.2（4.0）]的女性患者。42.1%的患者被认为对非索罗定治疗依从。其余57.9%的患者表示不依从/停药的主要原因是不良事件（62.2%）和缺乏临床益处（20.0%）。接受非索罗定治疗三个月后，疾病状态以及膀胱过度活动症症状给患者带来的困扰及其对生活质量的影响均有显著改善（p<0.0001）。大多数患者表示其当前的泌尿问题状态有很大改善/有所改善。
在常规临床实践中，高比例患者对非索罗定治疗依从，并在开始治疗三个月后感受到了该治疗带来的益处。然而，超过一半的研究人群未依从或停止治疗，主要原因是不耐受或缺乏疗效。
